Condition: Secondary Progressive Multiple Sclerosis · Sponsor: Zenas BioPharma (USA), LLC
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
This description comes directly from the study's public registry record.
Patient and Medical Information · 833-269-4696 · clinicaltrialsinfo@zenasbio.com
Patient and Medical Information · 833-269-4696 · clinialtrialsinfo@zenasbio.com
Always discuss trial participation with your own doctor first.
| Arizona Neuroscience Research, LLC | Phoenix, Arizona, United States | Recruiting |
| Perseverance Research Center, LLC (PRC) | Scottsdale, Arizona, United States | Recruiting |
| Fullerton Neurology and Headache Center | Fullerton, California, United States | Recruiting |
| Regina Berkovich MD, PhD Inc | West Hollywood, California, United States | Recruiting |
| SFM Clinical Research, LLC | Boca Raton, Florida, United States | Recruiting |
| Nova Clinical Research, LLC | Bradenton, Florida, United States | Recruiting |
| MS and Neuromuscular Center of Excellence | Clearwater, Florida, United States | Recruiting |
| Neurology Associates | Maitland, Florida, United States | Recruiting |
| Aqualane Clinical Research | Naples, Florida, United States | Recruiting |
| Josephson Wallack Munshower Neurology, Pc Suite 225 | Indianapolis, Indiana, United States | Recruiting |
| KC Research Center, PA Neurology Research Dept | Roeland Park, Kansas, United States | Recruiting |
| Boston Clinical Trials | Boston, Massachusetts, United States | Withdrawn |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07299019